Putative role of the mTOR/4E-BP1 signaling pathway in the carcinogenesis and progression of gastric cardiac adenocarcinoma

Molecular Medicine Reports

Volumn 7, Issue 2, 2013, Pages 537-542

  Yang, Hai Yan ^a   Xue, Li Ying ^a   Xing, Ling Xiao ^a   Wang, Juan ^a   Wang, Jun Ling ^a   Yan, Xia ^a   Zhang, Xiang Hong ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

4E BP1; EIF4E; Gastric cardiac adenocarcinoma; MTOR

Indexed keywords

INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GASTRIC CARDIAC ADENOCARCINOMA; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; STOMACH MUCOSA; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; AGED; DISEASE PROGRESSION; EUKARYOTIC INITIATION FACTOR-4E; GASTRIC MUCOSA; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PHOSPHOPROTEINS; PHOSPHORYLATION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84873862324     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1208     Document Type: Article

References (37)

1. Shah MA and Schwartz GK: Treatment of metastatic esophagus and gastric cancer. Semin Oncol 31: 574-587, 2004.
2. Crane SJ, Richard Locke G III, Harmsen WS, Diehl NN, Zinsmeister AR, Joseph Melton L III, et al: The changing incidence of oesophageal and gastric adenocarcinoma by anatomic sub-site. Aliment Pharmacol Ther 25: 447-453, 2007.
3. Zhao CY, Zhang XH, Xue LY, Xing LX, Wang JL, Li XM, et al: Analysis of the changing trends of frequency and localization of gastric cancers arising from different sites of the stomach in population of the high incidence area of esophageal and gastric cancers in Hebei province. Zhonghua Zhong Liu Za Zhi 30: 817-820, 2008 (In Chinese).
4. Tajima Y, Yamazaki K, Makino R, Nishino N, Masuda Y, Aoki S, et al: Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach. Br J Cancer 96: 631-638, 2007.
5. Faried LS, Faried A, Kanuma T, Aoki H, Sano T, Nakazato T, et al: Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. Mol Carcinog 47: 446-457, 2008.
6. Albert JM, Kim KW, Cao C and Lu B: Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 5: 1183-1189, 2006.
7. Mori H, Inoki K, Masutani K, Wakabayashi Y, Komai K, Nakagawa R, et al: The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun 384: 471-475, 2009.
8. Fingar DC and Blenis J: Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171, 2004.
9. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C and Blenis J: mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24: 200-216, 2004.
10. Azar R, Alard A, Susini C, Bousquet C and Pyronnet S: 4E-BP1 is a target of Smad4 essential for TGFbeta-mediated inhibition of cell proliferation. EMBO J 28: 3514-3522, 2009.
11. Oulhen N, Mulner-Lorillon O and Cormier P: eIF4E-binding proteins are differentially modified after ammonia versus intracellular calcium activation of sea urchin unfertilized eggs. Mol Reprod Dev 77: 83-91, 2010.
12. Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, et al: Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120: 1803-1810, 2007.
13. Yoon DH, Ryu MH, Park YS, Lee HJ, Lee C, Ryoo BY, et al: Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer 106: 1039-1044, 2012.
14. Siewert JR and Stein HJ: Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85: 1457-1459, 1998.
15. Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, Doan HQ, et al: Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg 210: 767-776, 2010.
16. Kruck S, Bedke J, Hennenlotter J, Ohneseit PA, Kuehs U, Senger E, et al: Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression. Oncol Rep 23: 159-163, 2010.
17. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, et al: Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10: 6779-6788, 2004.
18. Ji J and Zheng PS: Activation of mTOR signaling pathway contributes to survival of cervical cancer cells. Gynecol Oncol 117: 103-108, 2010.
19. Faivre S, Kroemer G and Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688, 2006.
20. Osaki M, Kase S, Adachi K, Takeda A, Hashimoto K and Ito H: Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45. J Cancer Res Clin Oncol 130: 8-14, 2004.
21. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK and Testa JR: AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23: 5853-5857, 2004.
22. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, et al: Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res 15: 1821-1829, 2009.
23. Murayama T, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, et al: Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer 100: 782-788, 2009.
24. Fingar DC, Salama S, Tsou C, Harlow E and Blenis J: Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16: 1472-1487, 2002.
25. Sabatini DM: mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6: 729-734, 2006.
26. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, et al: Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66: 1203-1212, 2006.
27. Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, et al: 4E-binding protein 1: a key molecular 'funnel factor' in human cancer with clinical implications. Cancer Res 67: 7551-7555, 2007.
28. Darb-Esfahani S, Faggad A, Noske A, Weichert W, Buckendahl AC, Müller B, et al: Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol 135: 933-941, 2009.
29. O'Reilly KE, Warycha M, Davies MA, Rodrik V, Zhou XK, Yee H, et al: Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res 15: 2872-2878, 2009.
30. Benavente S, Vergés R, Hermosilla E, Fumanal V, Casanova N, García A, et al: Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy. Int J Radiat Oncol Biol Phys 75: 1316-1322, 2009.
31. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW and Sonenberg N: eIF4E - from translation to transformation. Oncogene 23: 3172-3179, 2004.
32. Sonenberg N: Cap-binding proteins of eukaryotic messenger RNA: functions in initiation and control of translation. Prog Nucleic Acid Res Mol Biol 35: 173-207, 1988.
33. De Benedetti A and Harris AL: eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol 31: 59-72, 1999.
34. Culjkovic B, Topisirovic I and Borden KL: Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E. Cell Cycle 6: 65-69, 2007.
35. De Benedetti A and Graff JR: eIF4E expression and its role in malignancies and metastases. Oncogene 23: 3189-3199, 2004.
36. Wang R, Geng J, Wang JH, Chu XY, Geng HC and Chen LB: Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma. Lung Cancer 66: 237-244, 2009.
37. Topisirovic I, Ruiz-Gutierrez M and Borden KL: Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res 64: 8639-8642, 2004.